Caris Life Sciences (CAI) reported $812M in revenue for fiscal 2025, +97.0% year on year. That ranks #1909 by revenue among 2853 SEC filers and #179 in Healthcare. It posted a net loss of −$68.1M for the same year. Revenue has grown 62.9% a year on average since 2023 ($306M then). The fiscal 2025 balance sheet shows $1.1B in total assets, $796M in cash and $379M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $812M | +97.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $45.1M | +$302M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$68.1M | +$214M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $83.2M | +$328M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $16.3M | +92.6% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | +227.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $577M | +$3.1B | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $796M | +1,145.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $379M | +18.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $216M | −$510,000 | Open → |
| Q2 20262026-06-30 | $264M | −$637,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Caris Life Sciences, Inc.
- Ticker
- CAI
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0002019410
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KMar 3, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Myriad GeneticsMYGN | $825M | −$366M |
| Orthofix MedicalOFIX | $822M | −$92.2M |
| Ascendis PharmaASND | $814M | −$258M |
| Caris Life SciencesCAI | $812M | −$68.1M |
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Caris Life Sciences — Key figures |url=https://companiesranked.com/en/company/caris-life-sciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Caris Life Sciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/caris-life-sciencesBibTeX
@misc{companiesranked-en-company-caris-life-sciences-2026,
author = {{CompaniesRanked}},
title = {{Caris Life Sciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/caris-life-sciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0002019410-26-000016 · March 3, 2026
{{cite web |title=Caris Life Sciences — Key figures — 10-K (0002019410-26-000016) |url=https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/cai-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.